semaglutide ckd approval just got FDA-approved for kidney disease. This changes everything., January 2025. The FDA approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in semaglutide for chronic kidney disease

Conclusion GLP-1 receptor agonists have emerged as powerful agents that improve metabolic health lowering blood sugar, inducing weight loss, and reducing cardiovascular risk in patients with diabetes or obesity

Beyond that window, peptide degradation accelerates regardless of appearance

This pattern may indicate suboptimal dosing or individual pharmacokinetic variation

However, a 2022 study found that those who take semaglutides regained two-thirds of their prior weight loss after a year of being off the drug

As we grow older, cell renewal and repair slow down, which can be delayed by getting enough vitamins and nutrients, like vitamin B12